Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
about
Progress and potential: training in genomic pathologyCase report: anti-hormonal therapy in the treatment of ductal carcinoma of the parotid glandHigh-throughput profiling identifies clinically actionable mutations in salivary duct carcinoma.Subsets of salivary duct carcinoma defined by morphologic evidence of pleomorphic adenoma, PLAG1 or HMGA2 rearrangements, and common genetic alterations.Targeted next generation sequencing of parotid gland cancer uncovers genetic heterogeneity.Ductal activation of oncogenic KRAS alone induces sarcomatoid phenotypeIdentification of Targetable ERBB2 Aberrations in Head and Neck Squamous Cell Carcinoma.HER2 expression status in diverse cancers: review of results from 37,992 patients.Assessment of BRAF V600E (VE1) protein expression and BRAF gene mutation status in codon 600 in benign and malignant salivary gland neoplasms.Genetic alterations in salivary gland cancers.Database of genomic biomarkers for cancer drugs and clinical targetability in solid tumors.Implementation and utilization of the molecular tumor board to guide precision medicine.Genomic landscape of salivary gland tumors.Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.Oncogenic PIK3CA mutation and dysregulation in human salivary duct carcinoma.Genomic alterations in human epidermal growth factor receptor 2 (HER2/ERBB2) in head and neck squamous cell carcinoma.Development and clinical application of anti-HER2 monoclonal and bispecific antibodies for cancer treatment.Somatic mutations in salivary duct carcinoma and potential therapeutic targets.Androgen deprivation therapy for androgen receptor-positive advanced salivary duct carcinoma: A nationwide case series of 35 patients in The Netherlands.Salivary duct carcinoma: An aggressive salivary gland malignancy with opportunities for targeted therapy.Comprehensive genomic profiles of metastatic and relapsed salivary gland carcinomas are associated with tumor type and reveal new routes to targeted therapies.Significant and durable clinical benefit from trastuzumab in 2 patients with HER2-amplified salivary gland cancer and a review of the literature.Primary salivary gland malignancies: a review of clinicopathological evolution, molecular mechanisms and management.Lacrimal gland ductal carcinomas: Clinical, Morphological and Genetic characterization and implications for targeted treatment.The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.Prognostic and histogenetic roles of gene alteration and the expression of key potentially actionable targets in salivary duct carcinomas.Developing Androgen Receptor Targeting for Salivary Gland Cancers.A clinicopathological study and prognostic factor analysis of 177 salivary duct carcinoma patients from The Netherlands.Carcinoma ex-pleomorphic adenoma of the salivary glands has a high risk of progression when the tumor invades more than 2.5 mm beyond the capsule of the residual pleomorphic adenoma.Salivary duct carcinoma: Clinicopathologic features, morphologic spectrum, and somatic mutations.Clinical activity of androgen deprivation therapy in patients with metastatic/relapsed androgen receptor-positive salivary gland cancers.Intratumoral heterogeneity of HER2 protein and amplification of HER2 gene in salivary duct carcinoma.
P2860
Q34117277-0E733754-A1F1-44E3-B3BD-56C75F5A68D9Q34308966-59D6E9D9-7874-4C0D-A221-AA1A614917EAQ34436470-87114926-5607-45E1-9CDC-FE278DB862F2Q34532980-5BCB2EA7-49FD-44F7-A5A4-3823C0723FBFQ36228558-76F9E485-6121-4973-8F14-20617C2FE795Q36273532-BF750CD2-FE26-4B7D-A08F-F7A1F0FBEA1CQ37013995-7B0DBDB2-97B0-49E5-9C33-42F40E160C7CQ38364900-E2127165-302C-4E7F-9D65-AFCBBE074414Q38377890-30186AC8-64FC-47C8-BEE2-68726834849BQ38755879-2E3E022E-3117-4920-9652-9C1B7055333DQ39988198-D877DAEA-50C0-4DA2-B6A5-1808A971BB27Q41339458-4A21CCDB-63CE-47E5-ADCA-E96F5DFC4E24Q41546576-D4BCC6BD-E7ED-4335-B1A9-B9B4A4EDC617Q41906973-73E30E82-50EB-4F76-8F48-1A32C823E570Q41906992-84BE5CA2-4BA1-4478-AB98-49CA141D5CE2Q45408645-13A6A9A4-27B0-489C-8B28-0441199D1EEAQ47103332-061760DD-915D-4986-9710-96C92997BFA0Q47133482-074D42C5-545E-4831-9D99-28EF47B4A6E4Q47259493-5A03A7F9-14E7-48D2-99E6-7B85993843F3Q47859326-74A851A1-BFE9-40B4-B566-24B882EF1173Q47923316-122405EF-56BE-418D-BAD4-D408916647C0Q48123633-89359D9D-A3AA-4A00-A0F8-3D8C099FE02AQ48236697-9C039DD4-916B-4504-82A8-64E6A06A9D8FQ48249374-B370F870-B5C3-4EBA-951E-385801AA6685Q49511046-40334ED4-0E06-4E63-8793-5BE666316E96Q49688722-BE061D75-BB96-4FF4-B6B7-3F9276F9596FQ50132910-8B315547-0157-4EC7-9A52-83677C58E346Q52680181-10BC6DD3-81D1-4F22-B785-F376E8BE45F4Q53253351-F2EEDC3B-1CF3-4170-8FBC-5E5746D64B5AQ54226554-96E19E7A-ACA7-4458-97F8-EB9AD3413009Q54301350-EC6F6AC7-BA76-4E01-BFF4-7EDEC70831C4Q54323253-48BB645B-5203-4531-8EFC-14C09852DE0E
P2860
Detection of novel actionable genetic changes in salivary duct carcinoma helps direct patient treatment.
description
2012 nî lūn-bûn
@nan
2012 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Detection of novel actionable ...... elps direct patient treatment.
@ast
Detection of novel actionable ...... elps direct patient treatment.
@en
Detection of novel actionable ...... elps direct patient treatment.
@nl
type
label
Detection of novel actionable ...... elps direct patient treatment.
@ast
Detection of novel actionable ...... elps direct patient treatment.
@en
Detection of novel actionable ...... elps direct patient treatment.
@nl
prefLabel
Detection of novel actionable ...... elps direct patient treatment.
@ast
Detection of novel actionable ...... elps direct patient treatment.
@en
Detection of novel actionable ...... elps direct patient treatment.
@nl
P2093
P1476
Detection of novel actionable ...... elps direct patient treatment.
@en
P2093
Anthony John Iafrate
Arjola K Cosper
Daniel Deschler
Darrell R Borger
Dejan Juric
Donald P Lawrence
Dora Dias-Santagata
Johanna C Bendell
Julie M Batten
P304
P356
10.1158/1078-0432.CCR-12-1842
P407
P577
2012-11-27T00:00:00Z